Mr Alastair Maxwell

  • Honorary bioinformatics advisor (School of Molecular Biosciences)

email: Alastair.Maxwell@glasgow.ac.uk

Molecular Cell & Systems Biology, Lab 422, Davidson Building

Import to contacts

ORCID iDhttps://orcid.org/0000-0002-2414-2252

Publications

List by: Type | Date

Jump to: 2022 | 2020 | 2019 | 2018 | 2016
Number of items: 9.

2022

Dawson, J., Baine-Savanhu, F. K., Ciosi, M. , Maxwell, A. , Monckton, D. G. and Krause, A. (2022) A probable cis-acting genetic modifier of Huntington disease frequent in individuals with African ancestry. Human Genetics and Genomics Advances, 3(4), 100130. (doi: 10.1016/j.xhgg.2022.100130) (PMID:35935919) (PMCID:PMC9352962)

McAllister, B. et al. (2022) Exome sequencing of individuals with Huntington’s disease implicates FAN1 nuclease activity in slowing CAG expansion and disease onset. Nature Neuroscience, 25(4), pp. 446-457. (doi: 10.1038/s41593-022-01033-5) (PMID:35379994)

2020

Lu, A. T. et al. (2020) DNA methylation study of Huntington's disease and motor progression in patients and in animal models. Nature Communications, 11, 4529. (doi: 10.1038/s41467-020-18255-5) (PMID:32913184) (PMCID:PMC7484780)

Ellis, N. et al. (2020) Genetic risk underlying psychiatric and cognitive symptoms in Huntington’s Disease. Biological Psychiatry, 87(9), pp. 857-865. (doi: 10.1016/j.biopsych.2019.12.010) (PMID:32087949)

2019

Ciosi, M. et al. (2019) A genetic association study of glutamine-encoding DNA sequence structures, somatic CAG expansion, and DNA repair gene variants, with Huntington disease clinical outcomes. EBioMedicine, 48, pp. 568-580. (doi: 10.1016/j.ebiom.2019.09.020) (PMID:31607598) (PMCID:PMC6838430)

Lee, J.-M. et al. (2019) CAG repeat not polyglutamine length determines timing of Huntington’s disease onset. Cell, 178(4), 887-900.e14. (doi: 10.1016/j.cell.2019.06.036)

2018

Ciosi, M. et al. (2018) Glutamine Codon Usage and Somatic Mosaicism of the HTT CAG Repeat Are Modifiers of Huntington Disease Severity. EHDN 2018 Plenary Meeting, Vienna, Austria, 14-16 Sep 2018.

Levesley, J., Baine, F., Ciosi, M. , Maxwell, A. , Monckton, D. G. and Krause, A. (2018) A CIS-acting Modifier of Age at Diagnosis of Huntington Disease in Black South African Patients. EHDN 2018 Plenary Meeting, Vienna, Austria, 14-16 Sep 2018.

2016

Monckton, D. , Ciosi, M. , Mubarak, A., Cumming, S., Hamilton, G., Maxwell, A. , The International-Venezuela Collaborative Research Group, -, The Scottish Myotonic Dystrophy Genetic Variation Consortium, - and The Track-On HD Research Team, - (2016) Cryptic Polyglutamine Repeat Sequence Variation and Somatic Instability in Huntington’s Disease: Drivers of Pathology? European Huntington's Disease Network 9th Plenary Meeting, The Hague, The Netherlands, 16-18 Sep 2016. (doi: 10.1136/jnnp-2016-314597.2)

This list was generated on Sat Dec 21 15:32:14 2024 GMT.
Number of items: 9.

Articles

Dawson, J., Baine-Savanhu, F. K., Ciosi, M. , Maxwell, A. , Monckton, D. G. and Krause, A. (2022) A probable cis-acting genetic modifier of Huntington disease frequent in individuals with African ancestry. Human Genetics and Genomics Advances, 3(4), 100130. (doi: 10.1016/j.xhgg.2022.100130) (PMID:35935919) (PMCID:PMC9352962)

McAllister, B. et al. (2022) Exome sequencing of individuals with Huntington’s disease implicates FAN1 nuclease activity in slowing CAG expansion and disease onset. Nature Neuroscience, 25(4), pp. 446-457. (doi: 10.1038/s41593-022-01033-5) (PMID:35379994)

Lu, A. T. et al. (2020) DNA methylation study of Huntington's disease and motor progression in patients and in animal models. Nature Communications, 11, 4529. (doi: 10.1038/s41467-020-18255-5) (PMID:32913184) (PMCID:PMC7484780)

Ellis, N. et al. (2020) Genetic risk underlying psychiatric and cognitive symptoms in Huntington’s Disease. Biological Psychiatry, 87(9), pp. 857-865. (doi: 10.1016/j.biopsych.2019.12.010) (PMID:32087949)

Ciosi, M. et al. (2019) A genetic association study of glutamine-encoding DNA sequence structures, somatic CAG expansion, and DNA repair gene variants, with Huntington disease clinical outcomes. EBioMedicine, 48, pp. 568-580. (doi: 10.1016/j.ebiom.2019.09.020) (PMID:31607598) (PMCID:PMC6838430)

Lee, J.-M. et al. (2019) CAG repeat not polyglutamine length determines timing of Huntington’s disease onset. Cell, 178(4), 887-900.e14. (doi: 10.1016/j.cell.2019.06.036)

Conference or Workshop Item

Ciosi, M. et al. (2018) Glutamine Codon Usage and Somatic Mosaicism of the HTT CAG Repeat Are Modifiers of Huntington Disease Severity. EHDN 2018 Plenary Meeting, Vienna, Austria, 14-16 Sep 2018.

Levesley, J., Baine, F., Ciosi, M. , Maxwell, A. , Monckton, D. G. and Krause, A. (2018) A CIS-acting Modifier of Age at Diagnosis of Huntington Disease in Black South African Patients. EHDN 2018 Plenary Meeting, Vienna, Austria, 14-16 Sep 2018.

Monckton, D. , Ciosi, M. , Mubarak, A., Cumming, S., Hamilton, G., Maxwell, A. , The International-Venezuela Collaborative Research Group, -, The Scottish Myotonic Dystrophy Genetic Variation Consortium, - and The Track-On HD Research Team, - (2016) Cryptic Polyglutamine Repeat Sequence Variation and Somatic Instability in Huntington’s Disease: Drivers of Pathology? European Huntington's Disease Network 9th Plenary Meeting, The Hague, The Netherlands, 16-18 Sep 2016. (doi: 10.1136/jnnp-2016-314597.2)

This list was generated on Sat Dec 21 15:32:14 2024 GMT.